[Chronotherapy in arterial hypertension]

M Bendersky1

  • 1Departamento de Farmacología Aplicada, Universidad Nacional de Córdoba, Córdoba, Argentina.

Insights

Understanding blood pressure (BP) changes, like the morning BP surge, is key for cardiovascular and cerebrovascular risk. Ambulatory blood pressure monitoring (ABPM) aids in optimizing drug timing for better patient outcomes.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Blood pressure (BP) profiles in normotensive and hypertensive individuals are established.
  • The impact of BP variations on cardio- and cerebrovascular risk is known.
  • Ambulatory blood pressure monitoring (ABPM) has significantly advanced BP parameter knowledge.

Purpose of the Study:

  • To investigate the correlation between specific BP profile components and patient risk.
  • To explore the potential of chronotherapy guided by ABPM data.
  • To highlight the need for further research into BP modifications for risk prevention.

Main Methods:

  • Utilizing ambulatory blood pressure monitoring (ABPM) to analyze BP fluctuations.
  • Focusing on specific BP components, including nocturnal decrease and morning BP surge.
  • Reviewing existing data and identifying gaps in current research.

Main Results:

  • ABPM provides crucial insights into BP variability.
  • The nocturnal BP decrease and morning BP surge are identified as key risk indicators.
  • Current research on modifying these BP components for risk reduction is limited.

Conclusions:

  • Optimizing drug administration timing (chronotherapy) based on ABPM data may mitigate risks.
  • Further multicenter studies are essential to confirm the preventive impact of BP modifications.
  • Targeting specific BP dynamics holds promise for improved cardiovascular and cerebrovascular risk management.

Related Concept Videos

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
479
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
851
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
729
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
652
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.2K